Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.

Lung cancer (Amsterdam, Netherlands) - 1 May 2025

Bossé Yohan, Boudreau Dominique K, Saavedra Armero Victoria, Li Zhonglin, Tremblay Élody, Gaudreault Nathalie, Gagné Andréanne, Desmeules Patrice, Joubert Philippe

Abstract excerpt

There is still limited data on the prevalence of actionable molecular alterations in patients with early-stage resectable lung adenocarcinoma and prior studies reported important differences across geographic locations, demographic and pathologic characteristics. The tumors of 1,603 French Canadian patients with pathologically confirmed lung adenocarcinoma were interrogated using a 50-gene next-generation...

Read the complete abstract on PubMed

Topics

Humans
Female
Male
Aged
Lung Neoplasms
Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Mutation

High-Throughput Nucleotide Sequencing

Neoplasm Staging

ErbB Receptors

Aged, 80 and over

Biomarkers, Tumor

Canada

Source

Identifiers

PMID: 40209611
DOI: 10.1016/j.lungcan.2025.108530

Genes

EGFR
MET
ALK
BRAF
KRAS
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.PMID 40209611Read ↗

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.Semantic proximity Read ↗

Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutationsSemantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.Semantic proximity Read ↗

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.Semantic proximity Read ↗

Mapping the mutational terrain of lung adenocarcinoma: A Danish cohort study of 880 patients.Semantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The landscape of actionable genomic alterations in lung adenocarcinomas in IndiaSemantic proximity Read ↗

Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical ImplementationSemantic proximity Read ↗

Precision medicine and actionable alterations in lung cancer: A single institution experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.